ERBB2 and gastroesophageal junction adenocarcinoma: While the prognostic significance of HER2 in gastric/gastroesophageal junction adenocarcinoma and colorectal cancer remains debated, some studies suggest that HER2 amplification may be indicative of a poor prognosis [20–23].